Tuesday, Mar 5, 2002

Genentech Names Gene Murano Vice President, Regulatory Affairs

South San Francisco, Calif. -- March 5, 2002 --

Genentech, Inc. (NYSE: DNA) today announced the promotion of Gene Murano, Ph.D. to vice president, Regulatory Affairs. Murano will continue to report to Robert Garnick, Ph.D., senior vice president Regulatory, Quality and Compliance.

In his position, Murano is responsible for managing Genentech's regulatory activities surrounding the development, presentation and review of scientific data to obtain rapid approval of new drugs and biologics.

"Drawing upon his extensive scientific and regulatory background, Gene has made significant contributions to Regulatory Affairs since joining Genentech," said Garnick. "We are in our greatest commercialization phase in the history of the company, and I'm confident that under his leadership, Regulatory Affairs will continue to produce effective, high quality regulatory submissions to help us bring new products to patients with unmet medical needs."

Murano, 60, joined Genentech in 2000 as the senior director of Regulatory Affairs for the company's Washington, DC operations where he managed a program of regulatory policy development and implementation. In 2001, he assumed responsibility for the company's entire Regulatory Affairs department.

Prior to joining Genentech, Murano was director of the Division of Biologics and Biotechnology at U.S. Pharmacopeia. Prior to that appointment, he spent 20 years with the U.S. Food and Drug Administration (FDA) where his responsibilities included regulatory science and policy, quality assurance, technical research and standards development of biopharmaceuticals. His most recent positions at the FDA were associate director for Science, Office of Therapeutics Research and Review and deputy director, Division of Hematological Products. In these roles, he was responsible for the overall management of research and review activities of scientists working in the areas of hematological products, cytokine biology, monoclonal antibodies and cellular and gene therapies.

Murano holds a bachelor's degree in zoology from the University of Massachusetts. He was a graduate fellow and a NIH pre-doctoral fellow at Wayne State University, School of Medicine, where he earned both a master's degree and doctorate.

Genentech, Inc., is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fifteen of the currently approved products of biotechnology are based on or stem from Genentech science. Genentech markets ten products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.

# # #